Gliomas pp 155-164

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 171) | Cite as

Other Experimental Therapies for Glioma

Experimental therapies for glioma are mostly based on the insights into the cell biology of the tumors studied by modern methods including genomics and metabolomics. In surgery, intraoperative visualization of residual tumor by fluorescence has helped with the radicality of resection. Although temozolamide has become an important agent in the combined radiochemotherapy of newly diagnosed glioblastoma, understanding the underlying mechanisms of action and resistance has led to alterations in dosing schemes, which may be more beneficial than the introduction of new agents. Targeted therapies that have been highly promising in other solid tumors have been rather disappointing in gliomas, not for the lack of promising targets but most likely due to inefficacy of the reagents to reach their target. Direct delivery of reagents with interstitial infusion via convection-enhanced delivery has proven to be safe and effective, but the potential of that technology has not been exploited because many technicalities are still to be worked out, and better, more selective reagents are needed. Gene therapy has been reactivated with direct adeno-viral application to transfer HSV-Tk into tumor cells by adenoviral vectors, still awaiting final analysis. Oncolytic viruses are also under long-term refinement and await definitive pivotal clinical trials. Immunotherapy is currently focusing on vaccination strategies using either specifically pulsed dendritic cells or immunization with a specific peptide, which is unique to the vIII variant of the epidemal growth factor receptor. An area attracting immense attention for basic research as well as translation into clinical use is the characterization of neural stem cells and their theraputic potential when appropriately manipulated.

In general, there is a wide spectrum of specific neuro-oncological therapy developments, which are not only extrapolated from general oncology but also based on translational research in the field of glioma biology.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97: 12846–12851PubMedCrossRefGoogle Scholar
  2. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al. (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012PubMedCrossRefGoogle Scholar
  3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. (2008) Nature 455:1061–1068CrossRefGoogle Scholar
  4. de Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, van Gool S, Sabel M (2006) Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59:988–999; discussion 999–1000PubMedGoogle Scholar
  5. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson, RF, Yamashita Y, Krauze M, Noble CO, Drummond D, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS (2008) Canine model of convection-enhanced delivery of liposomes investigation. J Neurosurg 108:989–998PubMedCrossRefGoogle Scholar
  6. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS (2002) The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62:5657–5663PubMedGoogle Scholar
  7. Friedman HS, Keir S., Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME (2002) O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 1:43–948Google Scholar
  8. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95:652–660PubMedCrossRefGoogle Scholar
  9. Fu L, Zhu L, Huang Y, Lee TD, Forman SJ, Shih CC (2008) Derivation of neural stem cells from mesenchymal stemcells: evidence for a bipotential stem cell population. Stem Cells Dev 17:1109–1121PubMedCrossRefGoogle Scholar
  10. Geletneky K, Herrero YCM, Rommelaere J, Schlehofer JR (2005) Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med B Infect Dis Vet Public Health 52:327–330PubMedGoogle Scholar
  11. Glass R, Synowitz M, Kronenberg G, Walzlein JH, Markovic DS, Wang LP, Gast D, Kiwit J, Kempermann G, Kettenmann H (2005) Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci 25:2637–2646PubMedCrossRefGoogle Scholar
  12. Goetz C, Riva P, Poepperl G, Gildehaus FJ, Hischa A, Tatsch K, Reulen HJ (2003) Locoregional radio-immunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 62:321–328PubMedCrossRefGoogle Scholar
  13. GromeierM, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 97:6803–6808CrossRefGoogle Scholar
  14. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRefGoogle Scholar
  15. Hunt DP, Morris PN, Sterling J, Anderson JA, Joannides A, Jahoda C, Compston A, Chandran S (2008) A highly enriched niche of precursor cells with neuronal and glial potential within the hair follicle dermal papilla of adult skin. Stem Cells 26:163–172PubMedCrossRefGoogle Scholar
  16. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Yla-Herttuala S (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10:967–972PubMedCrossRefGoogle Scholar
  17. Kneifel S, Bernhardt P, Uusijarvi H, Good S, Plasswilm L, Buitrago-Tellez C, Muller-Brand J, Macke H, Merlo A (2007) Individual voxelwise dosimetry of targeted (90)Y-labelled substance P radiotherapy for malignant gliomas. Eur J Nucl Med Mol Imaging 34(9):1388–1395PubMedCrossRefGoogle Scholar
  18. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83–96PubMedCrossRefGoogle Scholar
  19. Kunwar S (2003) Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim f indings from ongoing phase 1 studies. Acta Neurochir (Suppl 88):105–111Google Scholar
  20. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman, JW, Puri RK (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844PubMedCrossRefGoogle Scholar
  21. Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362–1368PubMedCrossRefGoogle Scholar
  22. Li S, Gao Y, Tokuyama T, Yamamoto J, Yokota N, Yamamoto S, Terakawa S, Kitagawa M, Namba H (2006) Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites. Cancer Lett 251(2): 220–227PubMedCrossRefGoogle Scholar
  23. Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ (2006) Oncolytic HSV-1 for the treatment of brain tumours. Herpes 13:66–71PubMedGoogle Scholar
  24. Menei P, Capelle L, Guyotat J, Fuentes S, Assaker R, Bataille B, Francois P, Dorwling-Carter D, Paquis P, Bauchet L, Parker F, Sabatier J, Faisant N, Benoit JP (2005) Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 56:242–248; discussion 242–248PubMedCrossRefGoogle Scholar
  25. Parajuli P, Mathupala S, Mittal S, Sloan AE (2007) Dendritic cell-based active specific immuno-therapy for malignant glioma. Expert Opin Biol Ther 7:439–448PubMedCrossRefGoogle Scholar
  26. Phillips HS, Kharbanda S, Chen R, ForrestWF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173PubMedCrossRefGoogle Scholar
  27. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258–1260PubMedCrossRefGoogle Scholar
  28. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389–2401PubMedCrossRefGoogle Scholar
  29. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354–1361PubMedCrossRefGoogle Scholar
  30. Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Perez R, Large A (2006) Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5:375–379PubMedCrossRefGoogle Scholar
  31. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, WongTZ, Zhao XG, Zalutsky MR, Bigner DD (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397PubMedCrossRefGoogle Scholar
  32. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430–446PubMedCrossRefGoogle Scholar
  33. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, Giuliani G, Casi M (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 80:2733–2742PubMedCrossRefGoogle Scholar
  34. Roullin VG, Mege M, Lemaire L, Cueyssac JP, Venier-Julienne MC, Menei P, Gamelin E, Benoit JP (2004) Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization. Pharm Res 21:1558–1563PubMedCrossRefGoogle Scholar
  35. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I (2003) Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27–35PubMedCrossRefGoogle Scholar
  36. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD (2000) Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97:7503–7508PubMedCrossRefGoogle Scholar
  37. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, Probst A, Gratzl O, Reubi JC, Maecke R, Mueller-Brand J, Merlo A (2002) Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 29:486–493PubMedCrossRefGoogle Scholar
  38. Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR (2006) Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol 33:101–110PubMedCrossRefGoogle Scholar
  39. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMedGoogle Scholar
  40. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multi-centre phase III trial. Lancet Oncol 7:392–401PubMedCrossRefGoogle Scholar
  41. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576; discussion 564–576PubMedCrossRefGoogle Scholar
  42. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  43. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME (2007) Phase I trial of polif-eprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 25:399–404PubMedCrossRefGoogle Scholar
  44. Westphal M, Lamszus K, Hilt D (2003) Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neurochir Suppl 88:61–67PubMedGoogle Scholar
  45. Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS (2007) Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neurooncol 9:20–28Google Scholar
  46. Zalutsky MR (2005) Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med 46 (Suppl 1):151S–156SPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of NeurosurgeryUniversity Hospital Hamburg EppendorfHamburgGermany

Personalised recommendations